Considerable Unmet Needs Remain for T2DM, States GBI Research in Its Market Research Study Published at MarketPublishers.com09 Jan 2017 • by Natalie Aster
LONDON – There has been a fast-paced increase in the prevalence rate of type 2 diabetes mellitus (T2DM) over the past few decades, mainly due to surging obesity, an essential risk factor for the disease. This has led to a competitive and large market landscape, with a range of drug products competing with one another for various market segments, across manifold lines of treatment.
Over the past ten years, the competition has become stronger with the advent of dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT-2) inhibitors. Having had tremendous commercial success, these novel classes of drugs are currently well entrenched within the treatment algorithm.
Notwithstanding these developments, T2DM market still has huge unmet needs, which signifies a strong need for investment in first-in-class innovation. First-in-class drug products grab a lion’s share of the extensive T2DM pipeline, with a diversified range of first-in-class targets detected.
Topical research report “Frontier Pharma: Type 2 Diabetes Mellitus” elaborated by GBI Research offers an in-depth analysis of the market on a global level.
The study examines the pathophysiology of T2DM, typical co-morbidities and complications of the disease, the influence of the advent of new drug classes on the treatment algorithm, the hugest unmet needs within the marketplace. It discusses the innovative T2DM pipeline, covering the most prominent molecule types and molecular targets within the pipeline, promising first-in-class targets, difference of the ratio of first-in-class targets to first-in-class products by development stage and molecular target class. The report also canvasses the T2DM deals landscape.
More in-demand market research reports by our partner can be found at its page.